Net profit of Medicamen Biotech rose 82.88% to Rs 2.67 crore in the quarter ended September 2025 as against Rs 1.46 crore during the previous quarter ended September 2024. Sales rose 5.43% to Rs 47.17 crore in the quarter ended September 2025 as against Rs 44.74 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales47.1744.74 5 OPM %10.9411.87 - PBDT4.544.56 0 PBT2.681.96 37 NP2.671.46 83 Powered by Capital Market - Live News

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live News

Medicamen Biotech announced that the 32th Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live News

Net profit of Medicamen Biotech rose 59.26% to Rs 2.15 crore in the quarter ended June 2025 as against Rs 1.35 crore during the previous quarter ended June 2024. Sales declined 0.02% to Rs 43.04 crore in the quarter ended June 2025 as against Rs 43.05 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales43.0443.05 0 OPM %10.737.99 - PBDT3.933.33 18 PBT2.131.56 37 NP2.151.35 59 Powered by Capital Market - Live News

Net profit of Medicamen Biotech declined 27.43% to Rs 1.64 crore in the quarter ended June 2025 as against Rs 2.26 crore during the previous quarter ended June 2024. Sales declined 7.30% to Rs 38.45 crore in the quarter ended June 2025 as against Rs 41.48 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales38.4541.48 -7 OPM %10.4811.72 - PBDT3.944.76 -17 PBT2.173.02 -28 NP1.642.26 -27 Powered by Capital Market - Live News